Literature DB >> 30323050

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases.

Michael R Jacobs1,2, Ayman M Abdelhamed3,2, Caryn E Good3,2, Daniel D Rhoads3,2, Kristine M Hujer4,5, Andrea M Hujer4,5, T Nicholas Domitrovic4,5, Susan D Rudin4,5, Sandra S Richter6, David van Duin7, Barry N Kreiswirth8, Chris Greco9, Derrick E Fouts9, Robert A Bonomo10,5,11,12,13,14,15.   

Abstract

The activity of the siderophore cephalosporin cefiderocol is targeted against carbapenem-resistant Gram-negative bacteria. In this study, the activity of cefiderocol against characterized carbapenem-resistant Acinetobacter baumannii complex, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, and Enterobacteriaceae strains was determined by microdilution in iron-depleted Mueller-Hinton broth. The MIC90s against A. baumannii, S. maltophilia, and P. aeruginosa were 1, 0.25, and 0.5 mg/liter, respectively. Against Enterobacteriaceae, the MIC90 was 1 mg/liter for the group harboring OXA-48-like, 2 mg/liter for the group harboring KPC-3, and 8 mg/liter for the group harboring TEM/SHV ESBL, NDM, and KPC-2.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Enterobacteriaceaezzm321990; Gram-negative bacteria; S-649266; cefiderocol; cephalosporin; siderophore

Mesh：

Substances：

Year:  2018        PMID： 30323050      PMCID： PMC6325197          DOI： 10.1128/AAC.01801-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters.

Authors:  Takayuki Katsube; Shiro Miyazaki; Yukitoshi Narukawa; Martha Hernandez-Illas; Toshihiro Wajima
Journal:  Eur J Clin Pharmacol       Date:  2018-04-07       Impact factor: 2.953

2.  Multiplex PCR for detection of acquired carbapenemase genes.

Authors:  Laurent Poirel; Timothy R Walsh; Vincent Cuvillier; Patrice Nordmann
Journal:  Diagn Microbiol Infect Dis       Date:  2011-03-12       Impact factor: 2.803

3.  Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design.

Authors:  Michael D Huband; Akinobu Ito; Masakatsu Tsuji; Helio S Sader; Kelley A Fedler; Robert K Flamm
Journal:  Diagn Microbiol Infect Dis       Date:  2017-03-23       Impact factor: 2.803

4.  In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains.

Authors:  Naoki Kohira; Joshua West; Akinobu Ito; Tsukasa Ito-Horiyama; Rio Nakamura; Takafumi Sato; Stephen Rittenhouse; Masakatsu Tsuji; Yoshinori Yamano
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

5.  Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.

Authors:  Islam M Ghazi; Marguerite L Monogue; Masakatsu Tsuji; David P Nicolau
Journal:  Int J Antimicrob Agents       Date:  2017-10-27       Impact factor: 5.283

Review 6.  New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?

Authors:  H Wright; R A Bonomo; D L Paterson
Journal:  Clin Microbiol Infect       Date:  2017-09-08       Impact factor: 8.067

7.  Extensively drug-resistant pseudomonas aeruginosa isolates containing blaVIM-2 and elements of Salmonella genomic island 2: a new genetic resistance determinant in Northeast Ohio.

Authors:  Federico Perez; Andrea M Hujer; Steven H Marshall; Amy J Ray; Philip N Rather; Nuntra Suwantarat; Donald Dumford; Patrick O'Shea; T Nicholas J Domitrovic; Robert A Salata; Kalyan D Chavda; Liang Chen; Barry N Kreiswirth; Alejandro J Vila; Susanne Haussler; Michael R Jacobs; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

8.  Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa.

Authors:  Akinobu Ito; Toru Nishikawa; Shuhei Matsumoto; Hidenori Yoshizawa; Takafumi Sato; Rio Nakamura; Masakatsu Tsuji; Yoshinori Yamano
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

9.  In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).

Authors:  Meredith A Hackel; Masakatsu Tsuji; Yoshinori Yamano; Roger Echols; James A Karlowsky; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

10.  Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment.

Authors:  Takayuki Katsube; Roger Echols; Juan Camilo Arjona Ferreira; Heidi K Krenz; Jolene Kay Berg; Christopher Galloway
Journal:  J Clin Pharmacol       Date:  2016-11-22       Impact factor: 3.126
View more
  31 in total

1.  Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient.

Authors:  Zain I Alamarat; Jessica Babic; Truc T Tran; Susan H Wootton; An Q Dinh; William R Miller; Blake Hanson; Audrey Wanger; Joshua L Gary; Cesar A Arias; Norma Pérez
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 2.  Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Authors:  George G Zhanel; Alyssa R Golden; Sheryl Zelenitsky; Karyn Wiebe; Courtney K Lawrence; Heather J Adam; Temilolu Idowu; Ronald Domalaon; Frank Schweizer; Michael A Zhanel; Philippe R S Lagacé-Wiens; Andrew J Walkty; Ayman Noreddin; Joseph P Lynch Iii; James A Karlowsky
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 3.  Critical analysis of antibacterial agents in clinical development.

Authors:  Ursula Theuretzbacher; Karen Bush; Stephan Harbarth; Mical Paul; John H Rex; Evelina Tacconelli; Guy E Thwaites
Journal:  Nat Rev Microbiol       Date:  2020-03-09       Impact factor: 60.633

4.  Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the United States in 2017 and 2018.

Authors:  Joseph D Lutgring; Rocío Balbuena; Natashia Reese; Sarah E Gilbert; Uzma Ansari; Amelia Bhatnagar; Sandra Boyd; Davina Campbell; Jake Cochran; Jenn Haynie; Justina Ilutsik; Cynthia Longo; Stephanie Swint; J Kamile Rasheed; Allison C Brown; Maria Karlsson
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

5.  Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model.

Authors:  Iris H Chen; James M Kidd; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

6.  Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop Deletion.

Authors:  Akito Kawai; Christi L McElheny; Alina Iovleva; Ellen G Kline; Nicolas Sluis-Cremer; Ryan K Shields; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

7.  Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3.

Authors:  Saquib Malik; Monica Kaminski; David Landman; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

8.  ARGONAUT II Study of the In Vitro Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae.

Authors:  Michael R Jacobs; Caryn E Good; Andrea M Hujer; Ayman M Abdelhamed; Daniel D Rhoads; Kristine M Hujer; Susan D Rudin; T Nicholas Domitrovic; Lynn E Connolly; Kevin M Krause; Robin Patel; Cesar A Arias; Barry N Kreiswirth; Laura J Rojas; Roshan D'Souza; Richard C White; Lauren M Brinkac; Kevin Nguyen; Indresh Singh; Derrick E Fouts; David van Duin; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

9.  Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.

Authors:  Nathaniel C Warner; Luther A Bartelt; Anne M Lachiewicz; Kathleen M Tompkins; Melissa B Miller; Kevin Alby; Melissa B Jones; Amy L Carr; Jose Alexander; Andrew B Gainey; Robert Daniels; Anna-Kathryn Burch; David E Brown; Michael J Brownstein; Faiqa Cheema; Kristin E Linder; Ryan K Shields; Sarah Longworth; David van Duin
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

10.  In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe.

Authors:  Christopher Longshaw; Davide Manissero; Masakatsu Tsuji; Roger Echols; Yoshinori Yamano
Journal:  JAC Antimicrob Resist       Date:  2020-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.